retatrutide clinical trial doses produces up to 30.3% weight loss in Phase 3 What is Retatrutide? Key Facts
Description
Tirzepatide did not demonstrate detectable attenuation of weight reduction-induced decreases in sleeping or 24-h energy expenditure, but there was a reduction in respiratory exchange ratio in the tirzepatide treatment arm compared with that in the placebo arm, consistent with an increase in fat oxidation
This narrow definition puts the FDA in a bind
We do not provide guidance on human or animal use
These experiments were conducted in accordance with the ARRIVE guidelines
